[1] National Committee for Clinical Laboratory Standards. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Conidium-Forming Filamentous Fungi:Proposed Standard M38-P.Pennsylvania, NCCLS, 1998. [2] Vanden Bossche H, Warnock DW, Dupont B, et al. Mechanisms and clinical impact of antifungal drug resistance. J Med Vet Mycol,1994, 32 Suppl 1:189-202. [3] Scholer HJ, Polak A. Resistance to systemic antifungal agent. In:Bryan LE, ed, Antimicrobial Drug Resistance. Orlando:Academic,1984. 393-460. [4] 孙志坚,李若瑜,李东明,等.产孢丝状真菌NCCLS药敏实验方法的应用.中华检验医学杂志,2001,24:43-44. [5] 章强强,苏逸舟,李莉,等.100株临床分离致病酵母体外药敏试验分析.中华皮肤科杂志,2000,33:333-335. [6] Jessup C J, Ryder NS, Ghannoum MA. An evaluation of the in vitro activity of terbinafine. Med Mycol, 2000, 38:155-159. [7] McGinnis MR, Pasarell L. In vitro evaluation of terbinafine and itraconazole against dematiaceous fungi. Med Mycol, 1998, 36:243-246. [8] Johnson EM, Szekely A, Warnock DW. In-vitro activity of voriconazole, itraconazole and amphotericin B against filamentous fungi. J Antimicrob Chemother, 1998, 42:741-745. [9] Caligiorne RB, Resende MA, Melillo PH, et al. In vitro susceptibility of chromoblastomycosis and phaeohyphomycosis agents to antifungal drugs. Med Mycol, 1999, 37:405-409. |